Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients [Phase 2]

View source ↗

Summary

A Phase II study evaluating the efficacy and safety of TLC388 in patients with advanced/metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• TLC388

Snippet

Sponsor: Taiwan Liposome Company | Conditions: Advanced/Metastasis Renal Cell Carcinoma | Phase 2 | Status: COMPLETED